Will GLP-1 Agonists Weaken the Links between Obesity and Cancer?

Donal J. Brennan; Lydia Lynch

doi:10.1158/2159-8290.cd-25-0991

Will GLP-1 Agonists Weaken the Links between Obesity and Cancer?

Donal J. Brennan
, Lydia Lynch

Molecular Biology

Research output: Contribution to journal › Comment/debate › peer-review

1 Scopus citations

Abstract

Glucagon-like peptide 1 receptor agonists hold great promise to reverse some cancer risk in people living with obesity, and emerging clinical trials support this so far. However, some preclinical work and caveats from human studies highlight that more work is needed to understand the mechanisms and full potential of antiobesity medicines in cancer.

Original language	English (US)
Pages (from-to)	2209-2212
Number of pages	4
Journal	Cancer Discovery
Volume	15
Issue number	11
DOIs	https://doi.org/10.1158/2159-8290.cd-25-0991
State	Published - Nov 1 2025

All Science Journal Classification (ASJC) codes

Oncology

Access to Document

10.1158/2159-8290.cd-25-0991

Cite this

@article{ebf3e08f338d44a6985aad7a7deb0e58,

title = "Will GLP-1 Agonists Weaken the Links between Obesity and Cancer?",

abstract = "Glucagon-like peptide 1 receptor agonists hold great promise to reverse some cancer risk in people living with obesity, and emerging clinical trials support this so far. However, some preclinical work and caveats from human studies highlight that more work is needed to understand the mechanisms and full potential of antiobesity medicines in cancer.",

author = "Brennan, \{Donal J.\} and Lydia Lynch",

note = "Publisher Copyright: {\textcopyright} 2025 American Association for Cancer Research.",

year = "2025",

month = nov,

day = "1",

doi = "10.1158/2159-8290.cd-25-0991",

language = "English (US)",

volume = "15",

pages = "2209--2212",

journal = "Cancer Discovery",

issn = "2159-8274",